Business Wire

CIRIUM

Share
Vueling and Cirium Sign a Deal for Cirium Sky, to Dramatically Improve Airline Operational Performance

Vueling, an airline which forms part of IAG (International Airlines Group), has signed a landmark deal with Cirium, the aviation analytics company, to improve airline operational efficiencies through the Cirium Sky managed data warehouse and analytics solution.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221005005079/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Vueling and Cirium sign a deal for Cirium Sky, to dramatically improve airline operational performance (Photo: Business Wire)

The multi-year deal provides Vueling, with access to Cirium’s new data aviation warehouse and analytics capability.

This partnership will allow the airline to gain a unique insight from over 25 operational factors, and ultimately provide a best-in-traveller experience.

Cirium Sky will enable more effective flight planning, especially around disruption, to minimize delays for its customers.

Jeremy Bowen, Cirium CEO, said: “Our aviation data warehouse, Cirium Sky, is critical in supporting Vueling’s digital transformation initiatives and will enable the airline to improve flight operations, reduce travel delays and set the stage for operational excellence.”

Vueling is viewed by Cirium as the agile and innovative leader in IAG thanks to the implementation of several initiatives, including Vueling Transform, to unlock its full potential through digitization and low-cost leadership.

Oliver Iffert, Vueling Chief Operations Officer , said: “Coming out of the pandemic, Vueling is emerging even more efficient and competitive as we prioritize actionable insights backed by a wealth of data and context.”

“Data is key to assessing our operations and identifying ways to provide a passenger experience that stands out.”

“Using Cirium Sky, Vueling can plan flights more effectively and analyze flight delays based on accurate data. We will, as a result, drive a reduction in delays and minimize disruptions.”

The move to Cirium Sky transitions Vueling from using multiple data providers and data held in siloed systems to a single source of aviation data and analytics.

This strategic data and analytics partnership provides the airline with access to the industry’s largest data warehouse, which has a 360-degree view of flights, as well as prescriptive and predictive analytics to anticipate future operational challenges.

Added Bowen: “Improving operations is not only key for the traveller experience but also for tackling the liquidity issues and capacity recovery that airlines are facing in the wake of COVID-19.“

“By democratizing data and enabling smarter and faster decision making, airlines would see huge savings. We are delighted to partner with Vueling and drive value for their business.”

Cirium Sky is purpose-built to enable airlines, airports, financial institutions, aircraft manufacturers, and travel distributors to unlock the value in aviation data.

Find out more about Cirium Sky.

Ends

About Cirium

Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.

For further information please follow Cirium updates on LinkedIn or Twitter or visit www.cirium.com

About Vueling

Vueling, a company which forms part of IAG, is key in connectivity in Spain, the largest domestic market in Europe. For this winter 2022, the company has a network of more than 240 short and medium-haul routes in Europe, North Africa and the Middle East, which are operated with a fleet of Airbus A319, A320, A320neo and A321 models. In 2021, Vueling has won the World Airline Awards as the "Best Low Cost Airline in Europe".

As part of IAG, Vueling shares the vision of leading the field of sustainability within the global airline industry. That is why the company develops all its actions within the framework of the "Flightpath Net Zero" program, through which the goal of achieving net zero CO2 emissions in 2050 has been established.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221005005079/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release

Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release

Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release

MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye